DOTC also goes down.
D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives; D017277:Drug Approval; D015658:HIV Infections / Q000188:drug therapy*; D000882:Haplorhini; D006801:Humans; D017093:Liver Failure; D013872:Thionucleosides / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
C120719:2'-deoxy-3'-oxa-thiocytidine; D019380:Anti-HIV Agents; D013872:Thionucleosides; D003841:Deoxycytidine